...
首页> 外文期刊>Orthopaedic surgery >Role of Teriparatide in Glucocorticoid‐induced Osteoporosis through Regulating Cellular Reactive Oxygen Species
【24h】

Role of Teriparatide in Glucocorticoid‐induced Osteoporosis through Regulating Cellular Reactive Oxygen Species

机译:特立帕肽在糖皮质激素诱导的骨质疏松症中的作用,通过调节细胞活性氧的种类

获取原文

摘要

Objective To determine the signaling pathways mediated by teriparatide in MLO‐Y4 cell lines based on the evaluation of reactive oxygen species (ROS) through AKT pathways, which regulate apoptosis of bone cells. Methods We performed the DCFH‐DA assay to investigate the role of ROS in MLO‐Y4 cells caused by dexamethasone (Dex). Four groups were included: Dex group, Dex+NAC, Dex+ teriparatide group and control group (without any dispose). Real‐time reverse transcriptase polymerase chain reaction was used to test the SOD2 and Cat mRNA expression. Western blot (WB) was used to investigate the AKT and caspase‐3 protein expression. A Cell Counting Kit‐8 (CCK‐8) assay test was conducted to explore the cell viability, and we also studied the apoptosis through western blot assay. A glucocorticoid‐induced osteoporosis (GIOP) model was used to confirm the anti‐ROS and anti‐apoptosis ability of teriparatide. Results The CCK‐8 assay revealed that Dex reduced the proliferative capability of cells significantly, whereas incubation with teriparatide resulted in a remarkable increase in the proliferation of osteocytes. In addition, teriparatide can rescue the effect of inhibiting cell proliferation due to Dex treatment. Immunofluorescence analysis showed that ROS levels increased in Dex‐treated MLO‐Y4 cells when compared with control groups. However, the Dex+Teriparatide group showed less ROS when compared with the Dex group. The expression of Sod2 and Cat, two antioxidant enzymes crucial for ROS elimination, was decreased in the Dex group, indicating a defect of the enzymatic antioxidant system. Compared to the Dex group, incubation with teriparatide resulted in a significant decrease in caspase‐3 level; when compared with the control group, the caspase‐3 level was not significantly different, indicating that teriparatide can rescue apoptosis during Dex exposure. Moreover, teriparatide promotes the expression of AKT, and rescues the apoptosis effect caused by Dex. The results of immunofluorescence also showed that Akt was highly expressed in the teriparatide group when compared with the Dex group. The microstructural parameters Tb.Th, BV/TV, and Tb.N in the methylprednisolone (MPS) group were markedly reduced compared with the control group, but additional treatment with teriparatide could remarkably reverse the methylprednisolone‐induced reduction of these parameters. Moreover, the parameter Tb.Sp was significantly increased in the methylprednisolone group compared to the control group, and this increase could be inhibited by teriparatide. Conclusions Teriparatide can reduce the cellular ROS level caused by glucocorticoids to facilitate the proliferation of osteocytes through activating the AKT pathway. Meanwhile, the activated AKT can inhibit the activity of proteolytic enzyme caspase‐3 and prevent the activation of apoptosis cascade.
机译:目的基于通过调节骨细胞凋亡的AKT途径对活性氧(ROS)的评估,确定特立帕肽介导的MLO-Y4细胞系的信号传导途径。方法我们进行了DCFH-DA分析,以研究ROS在地塞米松(Dex)引起的MLO-Y4细胞中的作用。包括四组:Dex组,Dex + NAC,Dex + teriparatide组和对照组(无任何处置)。实时逆转录聚合酶链反应用于测试SOD2和Cat mRNA表达。 Western blot(WB)用于研究AKT和caspase-3蛋白的表达。进行了细胞计数试剂盒-8(CCK-8)分析测试以探索细胞活力,我们还通过蛋白质印迹分析研究了细胞凋亡。糖皮质激素诱导的骨质疏松症(GIOP)模型用于确认特立帕肽的抗ROS和抗凋亡能力。结果CCK-8分析显示,Dex显着降低了细胞的增殖能力,而与特立帕肽共同孵育可显着增加骨细胞的增殖。此外,特立帕肽可以挽救由于Dex处理而产生的抑制细胞增殖的作用。免疫荧光分析显示,与对照组相比,Dex处理的MLO-Y4细胞中ROS含量增加。然而,与Dex组相比,Dext + Teriparatide组显示出较少的ROS。 Dex组中Sod2和Cat(两种对ROS消除至关重要的抗氧化酶)的表达降低,表明该酶抗氧化系统存在缺陷。与Dex组相比,与特立帕肽共同孵育可导致caspase-3水平显着降低;与对照组相比,caspase-3水平没有显着差异,这表明特立帕肽可以在Dex暴露期间挽救细胞凋亡。此外,特立帕肽促进AKT的表达,并挽救由Dex引起的细胞凋亡作用。免疫荧光的结果还表明,与Dex组相比,特立帕肽组中Akt高表达。与对照组相比,甲基强的松龙(MPS)组的微结构参数Tb.Th,BV / TV和Tb.N显着降低,但是特立帕肽的进一步治疗可以显着逆转甲基强的松龙引起的这些参数的降低。此外,甲基泼尼松龙组中的参数Tb.Sp与对照组相比显着增加,并且这种增加可以被特立帕肽抑制。结论特立帕肽可通过激活AKT途径降低糖皮质激素引起的细胞ROS水平,促进骨细胞的增殖。同时,活化的AKT可以抑制蛋白水解酶caspase-3的活性,并阻止凋亡级联反应的激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号